Drawing for CAYARRA

USPTO serial 90492334

CAYARRA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
ELLINGER FATHY, JESSICA M
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CAYARRA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Laurence Rickles

Laurence Rickles TEVA PHARMACEUTICALS USA, Inc.400 Interpace ParkwayBuilding AParsippany, NJ 07054

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; ; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Oct 10, 2025MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 10, 2025ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 27, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 27, 2024EX5GSOU EXTENSION 5 GRANTED—
Aug 27, 2024EXT5SOU EXTENSION 5 FILED—
Aug 27, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 14, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 13, 2024EX4GSOU EXTENSION 4 GRANTED—
Mar 13, 2024EXT4SOU EXTENSION 4 FILED—
Mar 13, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 16, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 14, 2023EX3GSOU EXTENSION 3 GRANTED—
Sep 14, 2023EXT3SOU EXTENSION 3 FILED—
Sep 14, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 11, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 9, 2023EX2GSOU EXTENSION 2 GRANTED—
Mar 9, 2023EXT2SOU EXTENSION 2 FILED—
Mar 9, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 17, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 15, 2022EX1GSOU EXTENSION 1 GRANTED—
Sep 15, 2022EXT1SOU EXTENSION 1 FILED—
Sep 15, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 22, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 6, 2022ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Dec 21, 2021CHPBPOST PUBLICATION AMENDMENT - ENTERED—
Dec 21, 2021APETASSIGNED TO PETITION STAFF—
Dec 2, 2021EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Oct 28, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 28, 2021EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Oct 28, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 28, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 26, 2021ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Sep 28, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 28, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 8, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 20, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 13, 2021DOCKASSIGNED TO EXAMINER—
Apr 29, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 30, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance